PRL and breast cancer: In a sensitivity analysis excluding concomitant aripiprazole use time, duration of exposure to prolactin-increasing antipsychotics of 1–<5 years was associated with an aOR for breast cancer of 1.22 (95% CI = 1.05–1.42), and with an aOR of 1.47 (95% CI = 1.26–1.72) for ≥ 5 years exposure (table 4).